Vancomycin-associated renal dysfunction: Where are we now?

Pharmacotherapy

Volumn 34, Issue 12, 2014, Pages 1259-1268

  Carreno, Joseph J ^a   Kenney, Rachel M ^b   Lomaestro, Ben ^c  

^a ALBANY COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

^b HENRY FORD HOSPITAL   (United States)

^c ALBANY MEDICAL CENTER   (United States)

Author keywords

acute kidney injury; nephrotoxicity; vancomycin

Indexed keywords

AMINOGLYCOSIDE; AMPHOTERICIN B; HYPERTENSIVE AGENT; LOOP DIURETIC AGENT; VANCOMYCIN; ANTIINFECTIVE AGENT;

ACUTE KIDNEY FAILURE; BODY WEIGHT; CLINICAL FEATURE; CRITICAL ILLNESS; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG EXPOSURE; DRUG SAFETY; DRUG USE; GROUPS BY AGE; HEMODIALYSIS; HOSPITALIZATION; HUMAN; KIDNEY DYSFUNCTION; LENGTH OF STAY; LEUKEMIA; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MINIMUM INHIBITORY CONCENTRATION; MORTALITY; NEPHROTOXICITY; OXIDATIVE STRESS; REVIEW; RISK FACTOR; TREATMENT DURATION; TREATMENT OUTCOME; CHEMICALLY INDUCED; KIDNEY DISEASES;

ANTI-BACTERIAL AGENTS; HUMANS; KIDNEY DISEASES; VANCOMYCIN;

EID: 84919841807     PISSN: 02770008     EISSN: 18759114     Source Type: Journal    
DOI: 10.1002/phar.1488     Document Type: Review

References (50)

1. Liu C, Bayer A, Cosgrove SE, et al. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis 2011; 52: e18-55.
2. Levine DP,. Vancomycin: a history. Clin Infect Dis 2006; 42 (Suppl 1): S5-12.
3. Tattevin P, Cremieux AC, Rabaud C, Gauzit R,. Efficacy and quality of antibacterial generic products approved for human use: a systematic review. Clin Infect Dis 2014; 58: 458-69.
4. Tattevin P, Saleh-Mghir A, Davido B, et al. Comparison of six generic vancomycin products for treatment of methicillin-resistant Staphylococcus aureus experimental endocarditis in rabbits. Antimicrob Agents Chemother 2013; 57: 1157-62.
5. Lewis PO, Kirk LM, Brown SD,. Comparison of three generic vancomycin products using liquid chromatography-mass spectrometry and an online tool. Am J Health Syst Pharm 2014; 71: 1029-38.
6. Elyasi S, Khalili H, Dashti-Khavidaki S, Mohammadpour A,. Vancomycin-induced nephrotoxicity: mechanism, incidence, risk factors and special populations. A literature review. Eur J Clin Pharmacol 2012; 68: 1243-55.
7. Lodise TP, Patel N, Lomaestro BM, Rodvold KA, Drusano GL,. Relationship between initial vancomycin concentration-time profile and nephrotoxicity among hospitalized patients. Clin Infect Dis 2009; 49: 507-14.
8. Jeffres MN, Isakow W, Doherty JA, Micek ST, Kollef MH,. A retrospective analysis of possible renal toxicity associated with vancomycin in patients with health care-associated methicillin-resistant Staphylococcus aureus pneumonia. Clin Ther 2007; 29: 1107-15.
9. Minejima E, Choi J, Beringer P, Lou M, Tse E, Wong-Beringer A,. Applying new diagnostic criteria for acute kidney injury to facilitate early identification of nephrotoxicity in vancomycin-treated patients. Antimicrob Agents Chemother 2011; 55: 3278-83.
10. Chang CH, Lin CY, Tian YC, et al. Acute kidney injury classification: comparison of AKIN and RIFLE criteria. Shock 2010; 33: 247-52.
11. Pritchard L, Baker C, Leggett J, Sehdev P, Brown A, Bayley KB,. Increasing vancomycin serum trough concentrations and incidence of nephrotoxicity. Am J Med 2010; 123: 1143-9.
12. Rybak MJ, Lomaestro BM, Rotschafer JC, et al. Vancomycin therapeutic guidelines: a summary of consensus recommendations from the Infectious Diseases Society of America, the American Society of Health-System Pharmacists, and the Society of Infectious Diseases Pharmacists. Clin Infect Dis 2009; 49: 325-7.
13. Lodise TP, Lomaestro B, Graves J, Drusano GL,. Larger vancomycin doses (at least four grams per day) are associated with an increased incidence of nephrotoxicity. Antimicrob Agents Chemother 2008; 52: 1330-6.
14. van Hal SJ, Paterson DL, Lodise TP,. Systematic review and meta-analysis of vancomycin-induced nephrotoxicity associated with dosing schedules that maintain troughs between 15 and 20 milligrams per liter. Antimicrob Agents Chemother 2013; 57: 734-44.
15. Suzuki Y, Kawasaki K, Sato Y, et al. Is peak concentration needed in therapeutic drug monitoring of vancomycin? A pharmacokinetic-pharmacodynamic analysis in patients with methicillin-resistant Staphylococcus aureus pneumonia. Chemotherapy 2012; 58: 308-12.
16. Neely MN, Youn G, Jones B, et al. Are vancomycin trough concentrations adequate for optimal dosing? Antimicrob Agents Chemother 2014; 58: 309-16.
17. Hidayat LK, Hsu DI, Quist R, Shriner KA, Wong-Beringer A,. High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity. Arch Intern Med 2006; 166: 2138-44.
18. Cano EL, Haque NZ, Welch VL, et al. Incidence of nephrotoxicity and association with vancomycin use in intensive care unit patients with pneumonia: retrospective analysis of the IMPACT-HAP Database. Clin Ther 2012; 34: 149-57.
19. Carreno JJ, Jaworski A, Kenney RM, Davis SL,. Comparative incidence of nephrotoxicity by age group among adult patients receiving vancomycin. Infect Dis Ther 2013; 2: 8.
20. Nakayama H, Echizen H, Tanaka M, Sato M, Orii T,. Reduced vancomycin clearance despite unchanged creatinine clearance in patients treated with vancomycin for longer than 4 weeks. Ther Drug Monit 2008; 30: 103-7.
21. Horey A, Mergenhagen KA, Mattappallil A,. The relationship of nephrotoxicity to vancomycin trough serum concentrations in a veteran's population: a retrospective analysis. Ann Pharmacother 2012; 46: 1477-83.
22. Satoskar AA, Nadasdy G, Plaza JA, et al. Staphylococcus infection-associated glomerulonephritis mimicking IgA nephropathy. Clin J Am Soc Nephrol 2006; 1: 1179-86.
23. Hall RG 2nd, Hazlewood KA, Brouse SD, et al. Empiric guideline-recommended weight-based vancomycin dosing and nephrotoxicity rates in patients with methicillin-resistant Staphylococcus aureus bacteremia: a retrospective cohort study. BMC Pharmacol Toxicol 2013; 14: 12.
24. Roberts JA, Abdul-Aziz MH, Lipman J, et al. Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions. Lancet Infect Dis 2014; 14: 498-509.
25. Bosso JA, Nappi J, Rudisill C, et al. Relationship between vancomycin trough concentrations and nephrotoxicity: a prospective multicenter trial. Antimicrob Agents Chemother 2011; 55: 5475-9.
26. Davis SL, Scheetz MH, Bosso JA, Goff DA, Rybak MJ,. Adherence to the 2009 consensus guidelines for vancomycin dosing and monitoring practices: a cross-sectional survey of U.S. hospitals. Pharmacotherapy 2013; 33: 1256-63.
27. van Hal SJ, Fowler VG Jr,. Is it time to replace vancomycin in the treatment of methicillin-resistant Staphylococcus aureus infections? Clin Infect Dis 2013; 56: 1779-88.
28. Kullar R, Davis SL, Taylor TN, Kaye KS, Rybak MJ,. Effects of targeting higher vancomycin trough levels on clinical outcomes and costs in a matched patient cohort. Pharmacotherapy 2012; 32: 195-201.
29. Farber BF, Moellering RC Jr,. Retrospective study of the toxicity of preparations of vancomycin from 1974 to 1981. Antimicrob Agents Chemother 1983; 23: 138-41.
30. Pauly DJ, Musa DM, Lestico MR, Lindstrom MJ, Hetsko CM,. Risk of nephrotoxicity with combination vancomycin-aminoglycoside antibiotic therapy. Pharmacotherapy 1990; 10: 378-82.
31. Rybak MJ, Albrecht LM, Boike SC, Chandrasekar PH,. Nephrotoxicity of vancomycin, alone and with an aminoglycoside. J Antimicrob Chemother 1990; 25: 679-87.
32. Cosgrove SE, Vigliani GA, Fowler VG Jr, et al. Initial low-dose gentamicin for Staphylococcus aureus bacteremia and endocarditis is nephrotoxic. Clin Infect Dis 2009; 48: 713-21.
33. Vance-Bryan K, Rotschafer JC, Gilliland SS, Rodvold KA, Fitzgerald CM, Guay DR,. A comparative assessment of vancomycin-associated nephrotoxicity in the young versus the elderly hospitalized patient. J Antimicrob Chemother 1994; 33: 811-21.
34. Cappelletty D, Jablonski A, Jung R,. Risk factors for acute kidney injury in adult patients receiving vancomycin. Clin Drug Investig 2014; 34: 189-93.
35. Fullmer A, McCue D, Feng C,. Retrospective review of vancomycin-induced nephrotoxicity in patients with leukemia. J Oncol Pharm Pract 2013, Oct 31. [Epub ahead of print].
36. Burgess LD, Drew RH,. Comparison of the incidence of vancomycin-induced nephrotoxicity in hospitalized patients with and without concomitant piperacillin-tazobactam. Pharmacotherapy 2014; 34: 670-6.
37. Gomes DM, Smotherman C, Birch A, et al. Comparison of acute kidney injury during treatment with vancomycin in combination with piperacillin-tazobactam or cefepime. Pharmacotherapy 2014; 34: 662-9.
38. Meaney CJ, Hynicka LM, Tsoukleris MG,. Vancomycin-associated nephrotoxicity in adult medicine patients: incidence, outcomes, and risk factors. Pharmacotherapy 2014; 34: 653-61.
39. Moenster RP, Linneman TW, Finnegan PM, Hand S, Thomas Z, McDonald JR,. Acute renal failure associated with vancomycin and beta-lactams for the treatment of osteomyelitis in diabetics: piperacillin/tazobactam compared to cefepime. Clin Microbiol Infect 2013; 20: 384-9.
40. Ricci Z, Cruz D, Ronco C,. The RIFLE criteria and mortality in acute kidney injury: a systematic review. Kidney Int 2008; 73: 538-46.
41. Prabaker KK, Tran TP, Pratummas T, Goetz MB, Graber CJ,. Elevated vancomycin trough is not associated with nephrotoxicity among inpatient veterans. J Hosp Med 2012; 7: 91-7.
42. Walkey AJ, O'Donnell MR, Wiener RS,. Linezolid vs glycopeptide antibiotics for the treatment of suspected methicillin-resistant Staphylococcus aureus nosocomial pneumonia: a meta-analysis of randomized controlled trials. Chest 2011; 139: 1148-55.
43. Fu J, Ye X, Chen C, Chen S,. The efficacy and safety of linezolid and glycopeptides in the treatment of Staphylococcus aureus infections. PLoS ONE 2013; 8: e58240.
44. Fowler VG Jr, Boucher HW, Corey GR, et al. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N Engl J Med 2006; 355: 653-65.
45. Corrado ML,. Integrated safety summary of CANVAS 1 and 2 trials: phase III, randomized, double-blind studies evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections. J Antimicrob Chemother 2010; 65 (Suppl 4): iv67-71.
46. Wunderink RG, Niederman MS, Kollef MH, et al. Linezolid in methicillin-resistant Staphylococcus aureus nosocomial pneumonia: a randomized, controlled study. Clin Infect Dis 2012; 54: 621-9.
47. Cataldo MA, Tacconelli E, Grilli E, Pea F, Petrosillo N,. Continuous versus intermittent infusion of vancomycin for the treatment of Gram-positive infections: systematic review and meta-analysis. J Antimicrob Chemother 2012; 67: 17-24.
48. Verrall AJ, Llorin R, Tam VH, et al. Efficacy of continuous infusion of vancomycin for the outpatient treatment of methicillin-resistant Staphylococcus aureus infections. J Antimicrob Chemother 2012; 67: 2970-3.
49. Schmelzer TM, Christmas AB, Norton HJ, Heniford BT, Sing RF,. Vancomycin intermittent dosing versus continuous infusion for treatment of ventilator-associated pneumonia in trauma patients. Am Surg 2013; 79: 1185-90.
50. Neely MN, Youn G, Jones B, et al. Are vancomycin troughs adequate for optimal dosing? Antimicrob Agents Chemother 2014; 58: 309-16.